Takeda Completes Acquisition and Names New CEO of Nycomed

OSAKA, Japan, September 30, 2011 /PRNewswire/ –

Takeda Pharmaceutical Company Limited (“Takeda”, TSE: 4502) announced it
has completed its acquisition of Nycomed A/S (“Nycomed”) for 9.6 billion
Euro on a cash-free, debt-free basis and made Nycomed a wholly owned
subsidiary of Takeda effective the same day. Dr. Frank Morich has been named
CEO of Nycomed in addition to his current role as Executive Vice President
(EVP), International Operations (Americas/Europe), Takeda Pharmaceuticals
International, Inc., a wholly owned subsidiary of Takeda America Holdings,
Inc.

The transaction fits in with Takeda’s sustainable growth strategy
outlined in its 2011-2013 Mid-Range Plan (MRP). Takeda has a strong presence
in the Japanese and U.S. markets, while Nycomed has a significant business
infrastructure in Europe and high-growth emerging markets that will enhance
Takeda’s regulatory development expertise and commercialization capability.
In addition, the acquisition will bring Takeda an immediate and stable
increase in cash flow generated from annual revenue of more than 2.8 billion
Euro from the acquired business.

“The combination of both organizations will strengthen Takeda’s
performance during the 2011-2013 MRP period, and enable us to sustain medium
and long-term growth targets starting in fiscal 2015 and extending into the
next decade,” said Yasuchika Hasegawa, President & CEO of Takeda.
“Partnering the two organizations will have complementary effects and
further increase our potential to become a truly global pharmaceutical
company.”

“I look forward to bringing Takeda and Nycomed together to ensure we can
achieve enhanced revenue, growth and diversification, while maintaining the
strong momentum of both companies,” said Frank Morich. “The combined company
significantly broadens our coverage of the global pharmaceutical market to
more than 70 countries, increasing our global Rx sales ranking to 12th and
further strengthening our position in the industry.”

The combined company will have an active commercial presence in the
therapeutic areas of metabolic diseases, gastroenterology, oncology,
cardiovascular health, CNS diseases, inflammatory and immune disorders,
respiratory diseases and pain management, as well as having a well-balanced
presence in pharmaceutical markets of Japan, North America, Europe and
Asia/Emerging Markets.

The integration enhances the 1,260 billion yen of projected FY 2013
sales in 2011-13 MRP by more than 30 percent and improves the 280 billion
yen of projected FY 2013 operating income (excluding special factors derived
from business acquisition) in 2011-13 MRP by more than 40 percent. Takeda
will now start preparation of the consolidated financial outlook for its
fiscal 2011 ending March 31, 2012, and is planning to announce it upon
announcement of its financial results of fiscal 2011 2Q scheduled in
November.

About Takeda

Located in Osaka, Japan, Takeda is a research-based global company with
its main focus on pharmaceuticals. As the largest pharmaceutical company in
Japan and one of the global leaders of the industry, Takeda is committed to
strive towards better health for patients worldwide through leading
innovation in medicine. Additional information about Takeda is available
through its corporate website, http://www.takeda.com.

Takeda’s Forward-looking statements

This press release contains forward-looking statements. Forward-looking
statements include statements regarding Takeda’s plans, outlook, strategies,
results for the future, and other statements that are not descriptions of
historical facts. Forward-looking statements may be identified by the use of
forward-looking words such as “may,” “believe,” “will,” “expect,” “project,”
“estimate,” “should,” “anticipate,” “plan,” “assume,” “continue,” “seek,”
“pro forma,” “potential,” “target,” “forecast,” “guidance,” “outlook” or
“intend” or other similar words or expressions of the negative thereof.
Forward-looking statements are based on estimates and assumptions made by
management that are believed to be reasonable, though they are inherently
uncertain and difficult to predict. Investors are cautioned not to unduly
rely on such forward-looking statements.

Forward-looking statements involve risks and uncertainties that could
cause actual results or experience to differ materially from that expressed
or implied by the forward-looking statements. Some of these risks and
uncertainties include, but are not limited to, (1) the economic
circumstances surrounding Takeda’s business, including general economic
conditions in Japan, the United States and worldwide; (2) competitive
pressures and developments; (3) applicable laws and regulations; (4) the
success or failure of product development programs; (5) actions of
regulatory authorities and the timing thereof; (6) changes in exchange
rates; (7) claims or concerns regarding the safety or efficacy of marketed
products or product candidates in development; and (8) integration
activities with acquired companies.

The forward-looking statements contained in this press release speak
only as of the date of this press release, and Takeda undertakes no
obligation to revise or update any forward-looking statements to reflect new
information, future events or circumstances after the date of the
forward-looking statement. If Takeda does update or correct one or more of
these statements, investors and others should not conclude that Takeda will
make additional updates or corrections.

        Takeda Media and Investor Contacts:
        For Japanese Media and Global IR Inquiries:
        Seizo Masuda
        +81-3-3278-2037
        masuda_seizo@takeda.co.jp

        For Media Inquiries:
        Rebekah Childers
        Takeda
        +44(0)780-949-5101
        r.childers@tgrd.com

        Tobias Cottmann
        Nycomed
        +41-79-2177252
        tobias.cottmann@nycomed.com

SOURCE Takeda Pharmaceutical Company Limited